Latest Intellectual Property News

Page 5 of 89
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
Zimi has moved its next-generation Matter smart-home range closer to certification and production, while securing access to more than 10,000 retail outlets through Directed. But the company ended September with $344,000 in cash after burning $714,000 on operations, leaving further funding firmly in the frame.
Sophie Babbage
Sophie Babbage
28 Oct 2026
Aurora Labs has secured $6 million to expand production of its additively manufactured turbojet systems, with Walkinshaw Group joining the placement as a strategic investor. The raise will fund equipment, production infrastructure and the company’s push from early deliveries towards scaled commercial manufacturing.
Victor Sage
Victor Sage
28 Oct 2026
Sea Forest lifted first-quarter revenue 67% to A$3.4 million and generated a small operating cash inflow as it transitioned to a new distribution arrangement with Teys Australia. The agreement carries an indicative target of 480,000 cattle by June 2027, but the volume is not guaranteed and remains subject to implementation conditions.
Victor Sage
Victor Sage
28 Oct 2026
LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.
Victor Sage
Victor Sage
28 Oct 2026
Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.
Ada Torres
Ada Torres
28 Oct 2026
Immutep’s pivotal TACTI-004 lung cancer trial dominates a difficult FY26, with the failure widening the loss to A$79.3 million and triggering an impairment, cost cuts and a root cause review. The biotech retains A$68.9 million in cash, cash equivalents and term deposits, while its remaining investment case rests on IMP761 and selected efti studies.
Ada Torres
Ada Torres
27 Oct 2026
Hydrix reported stronger contract momentum and launched a defence strategy in FY26, but revenue fell, cash burn increased and its statutory loss widened to $6.72 million. The auditor identified a material uncertainty over the company’s ability to continue as a going concern, despite a $5.2 million capital raising and planned debt conversions.
Sophie Babbage
Sophie Babbage
27 Oct 2026
TALi Digital has appointed William Hamilton as chief executive and managing director, placing the former DigitalX executive at the centre of its Datasphere commercialisation push. The leadership change also moves Dr David Brookes to non-executive chair and includes a proposed performance-rights package subject to shareholder approval.
Victor Sage
Victor Sage
27 Oct 2026
Lumos Diagnostics has expanded FebriDx deployment to 265 US healthcare sites across 29 states, while product revenue rose 224% in the first quarter. The commercial gains came alongside a US$4.7 million operating cash outflow, slower-than-planned paediatric study enrolment and a Hologic development timeline pushed to around June 2028.
Ada Torres
Ada Torres
27 Oct 2026
Botanix’s Sofdra prescriptions rose 5.3% in the September quarter, but flat net revenue and a sharp cash decline have forced a major reset. The company is targeting a roughly 50% reduction in operating expenses while assessing licensing, acquisitions and broader strategic transactions.
Victor Sage
Victor Sage
27 Oct 2026
SCX.ai has reported positive operating cash flow in its first quarter as an ASX-listed company, alongside a 54% increase in annualised recurring revenue since its prospectus. The sovereign AI infrastructure provider also has more than 100 commercial customers and $23.9 million in cash, but its next test is converting new capacity and partnerships into durable revenue.
Sophie Babbage
Sophie Babbage
27 Oct 2026

Browse the archive

Full archive